XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative effect of ASC 326 adoption
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Accumulated deficit
Cumulative effect of ASC 326 adoption
Beginning Balance, Stockholders' equity at Dec. 31, 2020 $ 93,579   $ 22 $ 147,997 $ (2,124) $ (52,316)  
Beginning Balances, Stockholders' equity (in shares) at Dec. 31, 2020     21,958        
Issuance of common stock in public offering, net of issuance costs 59,525   $ 5 59,520      
Issuance of common stock in public offering, net of issuance costs (in shares)     4,600        
Exercise of stock awards and employee stock plan purchases 2,569     2,569      
Exercise of stock awards and employee stock plan purchases (in shares)     325        
Stock-based compensation 1,352     1,352      
Net income loss (23,225)         (23,225)  
Other comprehensive loss (2,298)       (2,298)    
Ending Balances, Stockholders' equity at Mar. 31, 2021 131,502   $ 27 211,438 (4,422) (75,541)  
Ending Balances, Stockholders' equity (in shares) at Mar. 31, 2021     26,883        
Beginning Balance, Stockholders' equity at Dec. 31, 2021 $ 131,907 $ (401) $ 27 223,336 (4,457) (86,999) $ (401)
Beginning Balances, Stockholders' equity (in shares) at Dec. 31, 2021 27,505   27,505        
Exercise of stock awards and employee stock plan purchases $ 156     156      
Exercise of stock awards and employee stock plan purchases (in shares)     98        
Stock-based compensation 2,671     2,671      
Net income loss (3,048)         (3,048)  
Subsidiary dissolution (68)       (68)    
Other comprehensive loss (268)       (268)    
Ending Balances, Stockholders' equity at Mar. 31, 2022 $ 130,949   $ 27 $ 226,163 $ (4,793) $ (90,448)  
Ending Balances, Stockholders' equity (in shares) at Mar. 31, 2022 27,603   27,603